v3.26.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:    
Research and development expenses $ 9,981 $ 12,249
Selling, general and administrative expenses 10,918 11,577
Loss from operations (20,899) (23,826)
Other income:    
Realized gain from sales of trading securities 1,126 1,640
Unrealized loss from trading securities (391) (22)
Interest income 692 389
Total other income 1,427 2,007
Net loss $ (19,472) $ (21,819)
Net loss per basic common share $ (33.06) $ (44.53)
Net loss per diluted common share $ (33.06) $ (44.53)
Weighted average number of common shares outstanding:    
Basic 589 490
Diluted 589 490